As a Roche (RHHBY.OB)
shareholder, I've been waiting for a while for the company to do
something with its life sciences research business, and its sequencing
business in particular. The company took a well-known run at Illumina (ILMN) and made a lesser-publicized joint bid for Life Technologies (LIFE).
With the options getting narrower, particularly with respect to systems
that could be commercialized on a near-term basis, Roche made its move -
signing a development and marketing agreement with Pacific Biosciences (PACB) covering sequencing, consumables, and related diagnostics products for the in vitro market.
I'd be curious to know if Roche has made any overtures toward Oxford Nanopore,
but that's neither here nor there at this point. For Pacific
Biosciences, this is a major public affirmation of the progress the
company has made to recover from system performance and reliability
problems that took a once-ballyhooed story to almost flirting with
bankruptcy. PacBio has already been a great pick for me (having
recommended the stock in an Alpha-Rich piece here), but I wouldn't
assume that there is all there is left in the story.
Click here to read the full article:
Did PacBio Just Sorta Sell Itself To Roche?
No comments:
Post a Comment